Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects

•MF59-adjuvanted, cell-based flu vaccine (aH5N1c) may be advantageous in a pandemic.•aH5N1c elicited robust antibody responses to heterologous A/H5N1 strains.•Responses were higher when assayed with microneutralization than HI. Vaccines are the main prophylactic measure against pandemic influenza. A...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccine Vol. 39; no. 47; pp. 6930 - 6935
Main Authors:	Chanthavanich, Pornthep, Versage, Eve, Van Twuijver, Esther, Hohenboken, Matthew
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 16.11.2021 Elsevier Limited
Subjects:	Adjuvants Adjuvants, Immunologic Adolescents Age Allergy and Immunology Antibodies Antibodies, Viral Antibody Formation Antibody response Antigens Avian flu Cell culture Cell Culture Techniques Child Children Coronaviruses COVID-19 cross immunity Cross-protection Dosage Guillain-Barre syndrome hemagglutination Hemagglutination inhibition Hemagglutination Inhibition Tests Hemagglutinins Humans Immunogenicity Influenza Influenza A Influenza A Virus, H5N1 Subtype Influenza pandemic vaccine Influenza Vaccines Influenza, Human - prevention & control MF59 adjuvant pandemic Pandemics Pediatrics Polysorbates Safety Seroconversion Severe acute respiratory syndrome coronavirus 2 Squalene Statistical methods Teenagers Vaccines Variance analysis Viruses United Kingdom > UK United States > US Influenza pandemic vaccine HI MN Immunogenicity MF59 adjuvant aH5N1c Safety Children Adolescents hemagglutination inhibition microneutralization MF59-adjuvanted, cell culture–based A/H5N1 influenza vaccine
ISSN:	0264-410X, 1873-2518, 1873-2518
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!